Second Attempt at First DNA-Based OUD Risk Test Wins FDA Approval

After an October 2022 advisory committee rejection of its initial genetic test for risk of opioid use disorder (OUD), SOLVD has won FDA approval for a revamped version of its DNA-based AvertD test.
Source: Drug Industry Daily